Apr 19, 2018 20:30 pm UTC| Business
EAST RUTHERFORD, N.J., April 19, 2018 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced a commitment to provide...
Glacier Bancorp, Inc. Announces Results for the Quarter Ended March 31, 2018
Apr 19, 2018 20:30 pm UTC| Business
1st Quarter 2018 Highlights: Net income of $38.6 million for the current quarter, an increase of $7.3 million, or 23 percent, over the prior year first quarter net income of $31.3 million. Pre-tax income of...
Entegra Financial Corp. Announces First Quarter 2018 Results
Apr 19, 2018 20:30 pm UTC| Business
FRANKLIN, N.C., April 19, 2018 -- Entegra Financial Corp. (the “Company”) (NASDAQ:ENFC), the holding company for Entegra Bank (the “Bank”), today announced earnings and related data for the three months ended March 31,...
Liberty Tax Announces Engagement of Independent Auditor
Apr 19, 2018 20:30 pm UTC| Business
VIRGINIA BEACH, Va., April 19, 2018 -- Liberty Tax, Inc. (NASDAQ:TAX) (the “Company”), the parent company of Liberty Tax Service, announced today that the Audit Committee of the Board of Directors of the Company has...
Larson Electronics LLC Releases 75kVA Isolated Transformer with 480V Delta Secondary Voltage
Apr 19, 2018 20:30 pm UTC| Business
KEMP, Texas, April 19, 2018 -- Leader in industrial lighting, Larson Electronics LLC, releases a new 3 phase energy efficient isolation transformer, suitable for indoor and outdoor use. This powerful and reliable design...
SHARC International Announces Non-Brokered $2.5 Million Private Placement
Apr 19, 2018 20:28 pm UTC| Business
VANCOUVER, British Columbia, April 19, 2018 -- SHARC International Systems Inc. (CSE:SHRC) (FSE:IWIA) (OTCQB:INTWF) ("SHARC") is pleased to announce a Non-Brokered Private Placement (the "Private Placement") and will...
Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market
Apr 19, 2018 20:24 pm UTC| Business
NEW YORK, April 19, 2018 -- MorphoSys AG (Nasdaq:MOR), a late-stage biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases, visited...